NewsBot
06-26-2009, 12:50 AM
DiaGenic ASA today announced that it has signed an option agreement with Merz Pharmaceuticals GmbH, an innovative developer of drugs for treatment of illnesses in neurology and psychiatry, to gain access to biomarkers for Mild Cognitive Impairment , increasingly considered a transitional stage to Alzheimer's disease.
More... (http://www.topix.net/med/neurology/2009/06/diagenic-to-provide-mci-biomarkers-for-merz-pharmaceuticals?fromrss=1)
(From Topix Neurology)
More... (http://www.topix.net/med/neurology/2009/06/diagenic-to-provide-mci-biomarkers-for-merz-pharmaceuticals?fromrss=1)
(From Topix Neurology)